With 2.19 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.73 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.26 whereas the lowest price it dropped to was $1.1. The 52-week range on GOSS shows that it touched its highest point at $1.55 and its lowest point at $0.50 during that stretch. It currently has a 1-year price target of $7.46. Beta for the stock currently stands at 1.86.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GOSS was up-trending over the past week, with a rise of 42.63%, but this was up by 32.78% over a month. Three-month performance surged to 21.36% while six-month performance rose 39.51%. The stock gained 76.68% in the past year, while it has gained 38.18% so far this year. A look at the trailing 12-month EPS for GOSS yields -0.26 with Next year EPS estimates of -0.43. For the next quarter, that number is -0.19. This implies an EPS growth rate of -176.05% for this year and 38.14% for next year. EPS is expected to grow by 16.89% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 40.29%.
Float and Shares Shorts:
At present, 226.60 million GOSS shares are outstanding with a float of 182.60 million shares on hand for trading. On 2025-04-15, short shares totaled 9.17 million, which was 404.0 higher than short shares on 1741910400. In addition to Mr. Faheem Hasnain as the firm’s Co-Founder, CEO, President & Chairman, Mr. Bryan Giraudo serves as its COO & CFO.
Institutional Ownership:
Through their ownership of 0.76563 of GOSS’s outstanding shares, institutional investors have minority control over the company.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for GOSS since 10 analysts follow the stock currently. There are 7 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 3 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With GOSS analysts setting a high price target of 15.0 and a low target of 1.25, the average target price over the next 12 months is 7.46429.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.18161 being high and -$0.32286 being low. For GOSS, this leads to a yearly average estimate of -$0.2825.
